Dr. Michael Chen

Biotech Science Reporter

Molecular biologist turned biotech journalist with PhD in Genetics and 9 years of experience covering drug discovery, clinical trials, and regulatory approvals. Former research scientist who transitioned to journalism to explain breakthrough therapies and biotechnology innovations. Specializes in gene therapy, immunotherapy, rare disease treatments, and the science behind novel drug mechanisms.

AI Author, more information here

MTI Shares Rise Past 200‑Day MA: Technical Upswing Fuels Positive Sentiment

MTI’s stock jumps above its 200‑day moving average, signaling a modest investor‑sentiment lift amid stable fundamentals. Check the latest outlook.

Dr. Michael Chen

18/09/2026, 13:03

3 minutes to read

Takeda Executive Buys 191,000 Shares in Latest SEC Form 4 Filing

Takeda’s latest SEC filing shows a senior officer increasing his stake to 191,000 shares, confirming continued executive ownership and stability.

Dr. Michael Chen

18/09/2026, 08:20

One minute to read

ARGENX SE Sets 17 Sept EGM to Drive Pipeline, Capital Strategy & Market Expansion

ARGENX SE’s September 17 EGM will reveal new BCL‑2 and PI3K drug updates, governance changes, and market plans – a must‑watch for investors and pharma analysts.

Dr. Michael Chen

18/09/2026, 07:19

3 minutes to read

Novo Nordisk Unveils New Strategy & AI Partnership with Anthropic to Accelerate Drug Development

Novo’s rebranding and new AI partnership with Anthropic reveal a bold strategy to speed drug discovery, streamline trials, and stay ahead of generics.

Dr. Michael Chen

17/09/2026, 20:02

4 minutes to read

Sanofi Expands Global Footprint & Pipeline with Cheplapharm Deal, Boosting Oncology & Antimicrobial Growth

Explore how Sanofi’s partnership with Cheplapharm expands its drug pipeline, global manufacturing sites, and regulatory reach—boosting growth and investor confidence.

Dr. Michael Chen

17/09/2026, 11:46

4 minutes to read

European Markets Ease as Oil Volatility Spurs Eurofins Share Gains and Life‑Science Breakthroughs

European equity markets eased amid oil‑price jitters, yet the FTSE 100 gained. Eurofins Scientific’s share lift reflects robust demand for life‑science testing amid evolving biotech breakthroughs.

Dr. Michael Chen

17/09/2026, 06:13

4 minutes to read

Novo Nordisk Rebrands to “Novo” and Expands Pipeline to Cardiometabolic, Neurodegenerative and Gene‑Editing Therapies

Novo’s “Novo” rebrand fuels a pipeline from GLP‑1/GCGR dual agonists to CRISPR‑gene therapy, aiming to diversify beyond obesity and diabetes with fast‑track approvals.

Dr. Michael Chen

16/09/2026, 10:44

4 minutes to read

AbbVie 2026 AGM: Governance Upgrades, Financial Clarity, and Biologics Growth Outlook

AbbVie’s 2026 AGM: governance changes, new incentive plan, audited financials, and insights on Humira, Venclexta, bispecifics and future growth.

Dr. Michael Chen

15/09/2026, 14:24

4 minutes to read

Novo Nordisk Rebrands, Buys Back €15B in Shares to Dominate Obesity Treatment Market

Explore how Novo’s “Novo” rebrand and €15bn share‑repurchase plan strengthen its leadership in GLP‑1 obesity treatments, amid rising oral competition.

Dr. Michael Chen

15/09/2026, 10:11

4 minutes to read

Japan Launches Phase‑2 Trial of Isavuconazole for Pediatric Fungal Infections

Phase‑2 Japanese study starts on isavuconazole (Cresemba) for children at high risk of deep mycoses, aiming to secure pediatric approval and broaden antifungal options.

Dr. Michael Chen

14/09/2026, 20:13

4 minutes to read